Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease

World Journal of Gastroenterology

Volumn 20, Issue 24, 2014, Pages 7718-7729

  Hu, Kuang Chun ^a,b,c   Wang, Horng Yuan ^a,b   Liu, Sung Chen ^a,b   Liu, Chuan Chuan ^a,b   Hung, Chung Lieh ^b   Bair, Ming Jong ^b   Liu, Chun Jen ^a,c   Wu, Ming Shiang ^c   Shih, Shou Chuan ^a,b  

^a MACKAY MEDICAL COLLEGE   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cardiovascular disease; Image assessment; Laboratory biochemistry; Nonalcoholic fatty liver disease; Noninvasive diagnosis

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 4; CYTOKERATIN 18; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 6; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CELL DEATH; CHEMICAL ANALYSIS; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ECHOGRAPHY; ELASTOGRAPHY; ENDOTHELIAL DYSFUNCTION; FIBROGENESIS; HOMEOSTASIS; HUMAN; IMAGING; INFLAMMATION; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS (TOPIC); NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PORTAL HYPERTENSION; PROTON NUCLEAR MAGNETIC RESONANCE; SCORING SYSTEM; THROMBOCYTE; BIOPSY; BLOOD; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; DISEASE COURSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME;

BIOLOGICAL MARKERS; BIOPSY; CARDIOVASCULAR DISEASES; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ELASTICITY IMAGING TECHNIQUES; HUMANS; INFLAMMATION MEDIATORS; LIVER; MAGNETIC RESONANCE IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84903123873     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i24.7718     Document Type: Article

References (91)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825 DOI: 10.1016/S0016-5085]
2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112 [PMID: 16447287 DOI: 10.1002/hep.20973]
3. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967 [PMID: 12809815 DOI: 10.1016/S0002-9270(03)00265-X]
4. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45 [PMID: 23703888 DOI: 10.1093/aje/kws448]
5. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-79 [PMID: 12512031 DOI: 10.1053/gast.2003.50004]
6. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007; 22: 794-800 [PMID: 17498218 DOI: 10.1111/j.1440-1746.2007.04952. x]
7. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol 2013; 10: 307-318 [PMID: 23458891 DOI: 10.1038/ nrgastro.2013.34]
8. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-961 [PMID: 14614602 DOI: 10.1007/ s00535-003-1178-8]
9. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-143 [PMID: 16706825]
10. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005; 129: 375-378 [PMID: 16012969 DOI: 10.1053/j.gastro.2005.05.041]
11. Thomas V, Harish K. Are we overestimating the risks of NASH? Gastroenterology 2006; 130: 1015-106; author reply 1016-1017 [PMID: 16530550 DOI: 10.1053/j.gastro.2006.01.078]
12. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38 [PMID: 17690317 DOI: 10.1161/ATVBAHA.107.147538]
13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952 [PMID: 15364185 DOI: 10.1016/S0140-6736(04)17018-9]
14. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/ NEJMra0912063]
15. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941 DOI: 10.1053/ j.gastro]
16. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]
17. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793 [PMID: 17565631 DOI: 10.1111/j.1440-1746.2007.05042.x]
18. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460 [PMID: 18038452 DOI: 10.1002/hep.21984]
19. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012; 56: 1363-1370 [PMID: 22314419 DOI: 10.1016/j.jhep.2011.12.025]
20. Wong VW, Chu WC, Wong GL, Chan RS, Chim AM, Ong A, Yeung DK, Yiu KK, Chu SH, Woo J, Chan FK, Chan HL. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415 [PMID: 21846782 DOI: 10.1136/gutjnl-2011-300342]
21. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798 [PMID: 18752331 DOI: 10.1002/hep.22429]
22. Papadia FS, Marinari GM, Camerini G, Murelli F, Carlini F, Stabilini C, Scopinaro N. Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies. Obes Surg 2004; 14: 952-958 [PMID: 15329185 DOI: 10.1381/0960892041719644]
23. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
24. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292 [PMID: 12774006 DOI: 10.1053/ jhep.2003.50229]
25. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-48 [PMID: 9448172 DOI: 10.1111/j.1572-0241.1998.044_c.x]
26. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004; 35: 1070-1082 [PMID: 15343508 DOI: 10.1016/j.humpath]
27. Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, Ricchiuti A, De Bortoli N, Marchi S, Pompella A, Passino C, Emdin M, Paolicchi A. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int 2012; 32: 629-634 [PMID: 22098947 DOI: 10.1111/j.1478-3231.2011.02673.x]
28. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-3014 [PMID: 10520861 DOI: 10.1016/S0002-9270(99)00507-9]
29. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001; 35: 195-199 [PMID: 11580141 DOI: 10.1016/S0168-8278(01)00094-0]
30. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation--mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32: 1771-1776 [PMID: 22815343 DOI: 10.1161/ATVBAHA.111.241869]
31. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-326 [PMID: 21040935 DOI: 10.1016/ j.metabol.2010.09.003]
32. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544 [PMID: 19291789 DOI: 10.1002/ hep.22845]
33. Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, Batur Y. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol 2009; 9: 16 [PMID: 19222849 DOI: 10.1186/1471-230X-9-16]
34. Koruk M, Tayşi S, Savaş MC, Yilmaz O, Akçay F, Karakök M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol 2003; 14: 12-17 [PMID: 14593532]
35. Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013; 1: 7 [PMID: 24252302 DOI: 10.1186/2050-7771-1-7]
36. Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 3782-3786 [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782]
37. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85 [PMID: 21953442 DOI: 10.1002/hep.24706]
38. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]
39. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010; 30: 391-401 [PMID: 20960378 DOI: 10.1055/s-0030-1267539]
40. Adams LA, Feldstein AE. Non-invasive diagnosis of onalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis 2011; 12: 10-16 [PMID: 21091933 DOI: 10.1111/j.1751-2980.2010.00471. x]
41. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, So WY, Cheng AY, Ng WF, Wong GL, Sung JJ, Chan HL. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1154-1161 [PMID: 16904946 DOI: 10.1016/j.cgh.2006.06.011]
42. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379 [PMID: 18510618 DOI: 10.1111/j.1572-0241.2007.01774.x]
43. García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, De la Mata M, Muntané J. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007; 17: 493-503 [PMID: 17608262 DOI: 10.1007/s11695-007-9087-1]
44. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalco-holic steatohepatitis. Front Biosci 2005; 10: 3093-3099 [PMID: 15970563 DOI: 10.2741/1765]
45. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis 2012; 16: 567-585 [PMID: 22824481 DOI: 10.1016/j.cld.2012.05.001]
46. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589 [PMID: 17661414 DOI: 10.1002/hep.21768]
47. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-1078 [PMID: 19585618 DOI: 10.1002/hep.23050]
48. Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844 [PMID: 17352011]
49. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 2013; 108: 1526-1531 [PMID: 23752877 DOI: 10.1038/ajg.2013.168]
50. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255-259 [PMID: 15633226]
51. Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013; 57: 103-111 [PMID: 22930399 DOI: 10.1002/hep.26030]
52. de Carvalho SC, Muniz MT, Siqueira MD, Siqueira ER, Gomes AV, Silva KA, Bezerra LC, D'Almeida V, de Oliveira CP, Pereira LM. Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J 2013; 12: 37 [PMID: 23547829 DOI: 10.1186/1475-2891-12-37]
53. Wang R, Lu Q, Feng J, Yin F, Qin C, Liu B, Liu Y, Liu X. Co-existence of non-alcoholic fatty liver disease with elevated alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine 2012; 41: 70-75 [PMID: 21796479 DOI: 10.1007/s12020-011-9511-0]
54. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-1938 [PMID: 17511754 DOI: 10.1111/j.1572-0241.2007]
55. Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, Kotze M. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011; 101: 477-480 [PMID: 21920102]
56. Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 1525-1530 [PMID: 22509085 DOI: 10.3748/wjg.v18.i13.1525]
57. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36 [PMID: 17567829 DOI: 10.1002/hep.21669]
58. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112 [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033]
59. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269 [PMID: 20801772 DOI: 10.1136/gut.2010]
60. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750 [PMID: 12198701 DOI: 10.1053/gast.2002.35354]
61. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]
62. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338 DOI: 10.1016/j.ultr asmedbio.2003.07.001]
63. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, Sung JJ, de Lédinghen V. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462 [PMID: 20101745 DOI: 10.1002/hep.23312]
64. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, Beaton M, Levstik M, Crotty P, Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208 [PMID: 21898479 DOI: 10.1002/hep.24624]
65. Petta S, Craxì A. Assessment by Fibroscan of fibrosis in non-alcoholic fatty liver disease: XL versus M probe? Hepatology 2012; 55: 1309; author reply 1309-1310 [PMID: 22307871 DOI: 10.1002/hep.25638]
66. Sporea I, Şirli R, Popescu A, Bota S, Badea R, Lupşor M, Focşa M, Dǎnilǎ M. Is it better to use two elastographic methods for liver fibrosis assessment? World J Gastroenterol 2011; 17: 3824-3829 [PMID: 21987625 DOI: 10.3748/wjg.v17.i33.3824]
67. Johnson NA, Walton DW, Sachinwalla T, Thompson CH, Smith K, Ruell PA, Stannard SR, George J. Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology 2008; 47: 1513-1523 [PMID: 18393289 DOI: 10.1002/ hep.22220]
68. Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, Cohen BL, Brenner D, Sirlin C, Loomba R. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-932 [PMID: 22431131 DOI: 10.1002/ hep.25731]
69. Mariappan YK, Glaser KJ, Ehman RL. Magnetic resonance elastography: a review. Clin Anat 2010; 23: 497-511 [PMID: 20544947 DOI: 10.1002/ca.21006]
70. Kim BH, Lee JM, Lee YJ, Lee KB, Suh KS, Han JK, Choi BI. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. J Magn Reson Imaging 2011; 34: 1110-1116 [PMID: 21932355 DOI: 10.1002/jmri.22723]
71. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-756 [PMID: 21460032 DOI: 10.1148/radiol.11101942]
72. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term followup of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/ hep.21327]
73. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-1584 [PMID: 17461452]
74. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602 [PMID: 20014114 DOI: 10.1002/ hep.23314]
75. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22 [PMID: 9878640 DOI: 10.1056/NEJM199901073400103]
76. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11: 1848-1853 [PMID: 15793879]
77. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607 [PMID: 18672311 DOI: 10.1016/j.jhep.2008.06.012]
78. Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 1411-1416 [PMID: 19702910 DOI: 10.1111/ j.1440-1746.2009.05872.x]
79. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29: 1325-1330 [PMID: 16732016 DOI: 10.2337/dc06-0135]
80. Lee YH, Wu YJ, Liu CC, Hou CJ, Yeh HI, Tsai CH, Shih SC, Hung CL. The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification. Radiol Res Pract 2011; 2011: 586785 [PMID: 22254139 DOI: 10.1155/2011/586785]
81. Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010; 55: 1752-1760 [PMID: 19688595 DOI: 10.1007/s10620-009-0935-9]
82. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010; 254: 393-400 [PMID: 20093511 DOI: 10.1148/radiol.09090769]
83. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-1727 [PMID: 21602530 DOI: 10.1136/gut.2011.242016]
84. Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF, Lehman BT, Fan S, Osypiuk E, Vita JA. Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation 2004; 109: 613-619 [PMID: 14769683 DOI: 10.1161/01. CIR.0000112565.60887.1E]
85. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-480 [PMID: 15981216 DOI: 10.1002/hep.20781]
86. Liu CC, Hung CL, Shih SC, Ko HJ, Lu YT, Wu YJ, Cheng HY, Hu KC, Yeh HI, Chang RE. Age-related differences in the clinical presentation, associated metabolic abnormality, and estimated cardiovascular risks from nonalcoholic fatty liver disease: a cross-sectional study from health evaluation center in Taiwan. Inter J Gerontol 2010; 4: 184-191 [DOI: 10.1016/j.ijge.2010.11.005]
87. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565 [PMID: 12432042 DOI: 10.1056/NEJMoa021993]
88. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322 [PMID: 14568895 DOI: 10.1161/01.CIR.0000097109.90783.FC]
89. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102 DOI: 10.1016/S0016-5085(98)70599-2]
90. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192 [PMID: 11266382 DOI: 10.1053/ gast.2001.23256]
91. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185 [PMID: 22297845 DOI: 10.1038/nature10809]